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ABSTRACT: 
Objective:  
To describe the outcome of a patient with refractory chronic paroxysmal hemicrania to 
occipital nerve stimulation. 
Background: 
Chronic paroxysmal hemicrania is a primary headache disorder exquisitely sensitive to 
indomethacin.  In patients unable to tolerate indomethacin, the therapeutic options are 
limited.  Occipital nerve stimulation is a promising therapy for other refractory headache 
conditions.  We report the first patient with medically refractory chronic paroxysmal 
hemicrania treated with occipital nerve stimulation. 
Methods: 
Following implantation of the occipital nerve stimulator in 2006, the patient kept prospective 
headache diaries.  Outcome was assessed by daily attack frequency. 
Results: 
After a follow-up of over 10-years, the patient reported a sustained efficacy of more than 
50% reduction in attack frequency and was pain-free at final follow-up.  The patient was able 
to stop indomethacin completely.  The patient had three successful pregnancies during 
follow-up.  One system revision was undertaken alongside an expected battery replacement 
to treat unequal paresthesia and pain over the electrodes. 
Conclusion: 
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Occipital nerve stimulation may offer an effective long-term treatment for chronic 
paroxysmal hemicrania in patients where indomethacin cannot be tolerated. 
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BACKGROUND 
Paroxysmal Hemicrania (PH) is a rare primary headache disorder characterized by recurrent 
attacks of severe, strictly unilateral pain, focused around the orbital, supraorbital and 
temporal regions, and associated with autonomic features.  Attacks can occur more than five 
times a day and last 2-30 minutes 1.  The disorder has an absolute response to indomethacin 
such that patients are rendered pain free by therapeutic doses.  Between 65% and 88% of 
patients suffer from the chronic form of PH where the attacks occur for more than one year 
without remission, or with remission periods lasting less than one month 1-3. 
Over 30% of patients report dose-limiting side-effects with indomethacin and approximately 
20% have to discontinue the drug due to tolerability problems 4.  Although several other 
drugs have been reported to have efficacy in PH, none offer the same magnitude of response.   
Occipital nerve stimulation (ONS) has been performed with positive outcomes in other 
primary headache conditions, including cluster headache.  Given that cluster headache is a 
condition with similar clinical and pathophysiological features to PH, we hypothesized that 
ONS may also be helpful to relieve medically refractory chronic paroxysmal hemicrania 
(CPH).  We report on the first patient with severe medically refractory CPH to undergo ONS. 
 
CASE REPORT 
A 26-year-old woman had a five-year history of recurrent attacks of excruciating strictly 
unilateral “sharp”, “electric shock-like” episodes of pain centered over the parietal and 
temporal regions radiating to the forehead and neck.  She reported daily attacks with no 
remission period since onset.  The attacks occurred predominately on the right side of the 
head (90% of attacks) although she had occasional unilateral side-variable attacks involving 
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the left side .  Attacks would occur between 6-8 times daily with at least three of these at 
night.  Attacks lasted an average of 15 minutes (ranging from 5-60 minutes) and were 
associated with ipsilateral conjunctival injection, ptosis, nasal blockage, rhinorrhea, facial 
sweating, photophobia and phonophobia.  She also complained of nausea and restlessness 
with attacks.  Triggers for the attacks included the smell of volatile substances (perfume, 
bleach), sleep deprivation and ingestion of cheese and chocolate.  The patient had complete 
resolution of pain with an oral indomethacin test (taken to a maximum of 75mg tds) and a 
diagnosis of CPH was made.  She was taking 150mg daily of indomethacin but was suffering 
severe gastric side effects despite proton-pump inhibitors. 
The patient had a history of co-existent episodic migraine with aura that had started at the age 
of 14 years.  This was very different to her CPH and was a moderately severe bilateral 
throbbing headache centered over the forehead.  Her migraine was associated with a visual 
aura, nausea, photophobia, phonophobia, osmophobia and motion sensitivity.  She suffered 
around four episodes of migraine a year each lasting between 12-24 hours.  These episodes 
responded to paracetamol. 
Other medical history included previous thyrotoxicosis treated successfully with carbimazole 
between the ages of 16-20 years.  She had since been euthyroid without treatment.  The 
patient reported a similar indomethacin-responsive headache disorder in her mother.  The 
patient was a junior doctor and had managed to continue working despite her headache 
disorder. 
She had tried multiple preventative medications including verapamil, rofecoxib, celecoxib, 
etoricoxib, methysergide, melatonin, topiramate, pizotifen and amitriptyline.  Greater 
occipital nerve blocks had proven ineffective. Given the intractable nature of her condition 
she was referred for a bilateral greater occipital nerve stimulator. 
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A bilateral greater occipital nerve stimulator was implanted in September 2006 using quad 
electrodes and a single IPG (Medtronic Prime Advanced; Medtronic Inc., Minneapolis, MN, 
USA).  Bilateral leads were employed to prevent side-shifting of attacks5.  This was placed 
on continuous bilateral stimulation with a pulse width of 450µs and a frequency of 70Hz.  
Over the course of treatment amplitude was altered to maintain constant occipital 
paraesthesiae and ranged from 0.3-0.7V.  Further details of occipital nerve stimulator 
implantation and programming techniques can be found in detail elsewhere6. 
Within two weeks of implant the patient reported attacks occurring at 1-2 times a day with no 
change in severity or duration.  After one month, attacks were occurring only once a week 
and she was able to completely stop Indomethacin.  Initial problems with painful or unequal 
stimulation on the left hand side were only partly solved with re-programming of the device. 
The patient also complained of constant discomfort along the track of the electrodes and neck 
stiffness.  
Efficacy was maintained until late 2008 when the patient noted intermittent paraesthesiae and 
a gradual increase in attack frequency.  The battery was found to be at the end of life and due 
to the complaint of unequal paresthesia and pain over the electrode tracks a decision was 
made to replace the whole system with octad electrodes and a rechargeable battery.  This was 
undertaken in October 2009 without complication.  Unfortunately, following the system 
replacement it took a number of months to regain the same level of efficacy as previously 
experienced.  In October 2011 attack frequency was back to once a week but she also 
reported a significant reduction in attack duration down to 5-minutes.  The patient has 
remained well controlled with ONS with only occasional breakthrough of attacks in 2013 and 
2015.  The episode in 2013 was associated with a sudden increase following a road traffic 
accident and loss of the stimulator control handset in the accident meaning that she could not 
adjust her stimulation levels herself.  The ONS system was found to be working well with no 
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lead fracture or displacement following the accident and the symptoms resolved within a few 
months of reprogramming.  Another transient increase in attack frequency was seen in early 
2015 triggered by stress.  The patient reported up to 10-20 attacks a day of severe pain lasting 
2-5 minutes each.  Due to the severity of the bout she was advised to restart Indomethacin 
and the device was reprogrammed. By mid-2015 she reported her attacks had improved to 3 
attacks daily lasting on average 4 –minutes and she had been able to stop Indomethacin.  The 
ONS was reprogrammed and the patient remained pain free until review in early-2017. 
Since the ONS implant, the patient has had three successful pregnancies with no issues from 
the implant occurring in any.  During all pregnancies she was able to control her PH well and 
not use Indomethacin.  She did report an increase in her episodic migraines during her second 
pregnancy but these settled after delivery. 
 
DISCUSSION 
This article reports the first patient to receive bilateral ONS for CPH.  Similar sustained 
efficacy has been noted in chronic cluster headache and hemicrania continua, two conditions 
sharing both clinical and pathophysiological features with CPH 3, 7.  The patient reported a 
delay of around one month to initial improvement and nearly 8-12 months to regain that level 
of improvement following battery depletion and ONS revision.  Similarly, she reported a 
gradual increase in attack frequency as the battery failed over a number of months.  These 
time delays have been consistently reported in the series of other headache conditions and 
argue against a placebo response as the cause of improvement. 
The long-term control of the attacks was interspersed with occasional bouts of attacks.  These 
were controlled with reprogramming of the ONS device.  This observation suggests that ONS 
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is modifying the neural network involved in pain generation but does not modify the natural 
history of the condition with periods of remissions and exacerbations.  It is important that 
patients undergoing the treatment are counseled that a resurgence of attacks does not mean 
treatment failure but is a normal and expected observation. 
We conclude that ONS may offer an effective long-term treatment for medically refractory 
CPH in patients where indomethacin cannot be tolerated. 
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